Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients

Germann, N.; Brienza, S.; Rotarski, M.; Émile, Jean-François; Palma, Mario Di; Musset, M; Reynès, M; Soulié, P; Cvitkovic, Esteban; Misset, Jean-Louis

doi:10.1023/a:1008310708853

Cited by 42 publications

(18 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This may be important as some studies suggest that patients who undergo ASCT in CR do better than those in PR (Moskowitz et al, 1999). Oxaliplatin, which is a diaminocyclohexane platinum, has an RR of 40% in patients with relapsed and refractory NHL, and is also active in patients resistant to cisplatin (Germann et al, 1999). As oxaliplatin is not associated with nephrotoxicity and ototoxicity (Chau et al, 2001), it may be an alternative for patients who are not suitable or who discontinue treatment with cisplatin because of nephrotoxicity and ototoxicity.…”

Section: Discussionmentioning

confidence: 99%

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma

Waters

Cunningham

et al. 2005

Br J Cancer

View full text Add to dashboard Cite

There is currently no standard salvage chemotherapy regimen in relapsed and refractory lymphoma. Gemcitabine is a novel nucleoside analogue, which acts synergistically with cisplatin both in vitro and in clinical studies. We evaluated the combination of gemcitabine, cisplatin and methylprednisolone (GEM-P) in 41 heavily pretreated patients with relapsed and refractory Hodgkin's and non-Hodgkin's lymphoma. The best-achieved response rate (RR) was 79% (95% CI 64 -91), with a complete RR of 21%. In patients with chemo-resistant disease, the RR was 63%. Myelosuppression was the main toxicity, the incidence of Grade 3 or 4 anaemia, neutropenia and thrombocytopenia was 17.1, 61.0 and 53.7% respectively. Only one patient had neutropenic sepsis and none of the patients suffered from haemorrhage. Grade 3 or 4 nonhaematological toxicity was minimal and stem cell mobilisation was not inhibited. GEM-P is an effective salvage regimen and its use prior to autologous stem cell transplant warrants further investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma

Waters

Cunningham

et al. 2005

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Oxaliplatin is part of the therapeutic standard regimens for the treatment of metastatic colorectal cancer in combination with fluorouracil/leucovorin (Giacchetti et al, 2000;de Gramont et al, 2000). Oxaliplatin has also been used as a single agent in this disease and other malignancies (Faivre et al, 1999;Germann et al, 1999;Garufi et al, 2001). Besides treatment of patients with metastatic disease, oxaliplatin is also approved for adjuvant protocols (André et al, 2004).…”

mentioning

confidence: 99%

Oxaliplatin-DNA adduct formation in white blood cells of cancer patients

et al. 2008

View full text Add to dashboard Cite

In this study, we investigated the kinetics of oxaliplatin-DNA adduct formation in white blood cells of cancer patients in relation to efficacy as well as oxaliplatin-associated neurotoxicity. Thirty-seven patients with various solid tumours received 130 mg m À2 oxaliplatin as a 2-h infusion. Oxaliplatin-DNA adduct levels were measured in the first cycle using adsorptive stripping voltammetry. Platinum concentrations were measured in ultrafiltrate and plasma using a validated flameless atomic absorption spectrometry method. DNA adduct levels showed a characteristic time course, but were not correlated to platinum pharmacokinetics and varied considerably among individuals. In patients showing tumour response, adduct levels after 24 and 48 h were significantly higher than in nonresponders. Oxaliplatin-induced neurotoxicity was more pronounced but was not significantly different in patients with high adduct levels. The potential of oxaliplatin-DNA adduct measurements as pharmacodynamic end point should be further investigated in future trials.

show abstract

“…The targeted response rate for this study of 20% lies well within the 90% confidence interval for the evaluable population, which indicates that SAM486A has some antitumor activity. The response rate was lower than that reported for some other single agent studies in relapsed or refractory NHL, including rituximab (22,29), oxaliplatin (30), or Bendamustin (31), but comparable or better than in other single drug studies: (a) infusional Vinorelbine showed an overall response rate of 18% in aggressive NHLs (32); and (b) Paclitaxel was reported with 15% ORR in the same disease (33). However, it is impossible to compare the results of this study to other single agent studies because of differences in patient population and treatment regimens.…”

Section: Discussionmentioning

confidence: 51%

“…MGBG yielded response rates between 30 and 50% in heavily pretreated or refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's disease patients (4, 6 -8). Response rates in patients with acute myeloid leukemia were also substantial (30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44)Ref. 4).…”

Section: Introductionmentioning

confidence: 99%

Clinical Efficacy, Tolerability, and Safety of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma

Pless

Belhadj²,

Menssen

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: SAM486A is a new inhibitor of S-adenosylmethionine-decarboxylase, a key enzyme for polyamine biosynthesis. It is more potent than the first generation Sadenosyl-methionine-decarboxylase inhibitor methylglyoxal bis-guanylhydrazone. This Phase IIa study reports the findings of SAM486A monotherapy in patients with refractory or relapsed non-Hodgkin's lymphoma (NHL).Patients and Methods: Forty-one previously treated patients with either diffuse large cell, follicular, or peripheral T-cell NHL were treated i.v. with 100 mg/m 2 SAM486A as a daily 1-h infusion for 5 days repeated every 3 weeks. Treatment was continued for a total of eight cycles or until disease progression.Results: Two patients, both with large B-cell lymphoma, showed a complete response at cycle 3 that was maintained for >13 and >28 months. Five patients had a partial response, and 3 had stable disease at last follow-up. The overall response rate (complete response plus partial response) was 18.9% for evaluable patients (7 patients). Anemia was the primary hematological toxicity and observed in 7 (17.1%) patients. Five patients experienced grade 3/4 anemia. Four patients (9.8%) experienced grade 3/4 febrile neutropenia and grade 3/4 thrombocytopenia, respectively. Nonhematological toxicities were mild to moderate in intensity. The most frequent side effects were nausea (39%), vomiting (22%), diarrhea (19.5%), asthenia (17.1%), abdominal pain (14.6%), and flushing (9.8%).Conclusion: SAM486A has a promising clinical activity in patients with poor prognosis NHL and manageable safety profile. To further define the role of SAM486A, in the treatment of NHL, additional studies are warranted.

show abstract

Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients

Abstract: Oxaliplatin is an active agent in relapsed/refractory NHL, including the MCL type. Its safety profile makes this agent a good candidate for the development of combined salvage regimens. Further phase II studies are needed to confirm these preliminary results.

Cited by 42 publications

References 12 publications

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma

Oxaliplatin-DNA adduct formation in white blood cells of cancer patients

Clinical Efficacy, Tolerability, and Safety of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma

Contact Info

Product

Resources

About